Method for treating idiopathic pulmonary fibrosis

Abstract

Aspects of the disclosure relate to a method for treating idiopathic pulmonary fibrosis (IPF) in a patient with N-acetylcysteine (NAC) comprising administering NAC to a patient after a sample from the patient has been genotyped and determined to be any one of: a) homozygous or heterozygous for a thymine at the single nucleotide polymorphism rs3750920; b) homozygous or heterozygous for guanine at the single nucleotide polymorphism rs5743894; or c) homozygous or heterozygous for thymine at the single nucleotide polymorphism rs35705950.

1 . A method for treating idiopathic pulmonary fibrosis (IPF) in a patient with N-acetylcysteine (NAC) comprising administering NAC to a patient after a sample from the patient has been genotyped and determined to be any one of:
 a) homozygous or heterozygous for a thymine at the single nucleotide polymorphism rs3750920;   b) homozygous or heterozygous for guanine at the single nucleotide polymorphism rs5743894; or   c) homozygous or heterozygous for thymine at the single nucleotide polymorphism rs35705950.   
     
     
         2 . The method of  claim 1 , wherein the patient is determined to be homozygous for a thymine at the single nucleotide polymorphism rs3750920. 
     
     
         3 . A method for treating idiopathic pulmonary fibrosis (IPF) in a patient with a combination therapy comprising prednisone, azathioprine, and N-acetylcysteine (PAN) comprising administering PAN to a patient after a biological sample from the patient has been genotyped and determined to be homozygous or heterozygous for thymine at the single nucleotide polymorphism rs3750920. 
     
     
         4 . The method of  claim 1 , wherein position 3074 upstream of the MUC5B gene has been sequenced. 
     
     
         5 . The method of  claim 1 , wherein position 581 in the nucleotide coding sequence of TOLLIP has been sequenced. 
     
     
         6 . The method of  claim 1 , wherein position 6120 in genomic DNA of the TOLLIP gene has been sequenced. 
     
     
         7 . The method of  claim 1 , wherein genotyping comprises amplifying a nucleic acid sequence complementary or identical to a region of the MUC5B genomic DNA 3074 nucleotides upstream of the MUC5B gene. 
     
     
         8 . The method of  claim 1 , wherein the patient was receiving one or more of NAC or PAN therapy prior to genotyping. 
     
     
         9 . The method of  claim 1 , wherein sequencing comprises amplifying a nucleic acid sequence complementary or identical to a region of the TOLLIP coding sequence that comprises position 581 or a region of the genomic DNA of the TOLLIP gene that comprises position 6120. 
     
     
         10 . The method of  claim 9 , wherein amplifying comprises using polymerase chain reaction (PCR). 
     
     
         11 - 12 . (canceled) 
     
     
         13 . The method of  claim 1 , wherein the biological sample is a blood sample, a fecal sample, or a mouth swab. 
     
     
         14 . The method of  claim 1 , wherein the biological sample comprises genomic DNA. 
     
     
         15 - 18 . (canceled) 
     
     
         19 . A method for treating idiopathic pulmonary fibrosis in a patient in need thereof comprising:
 a) obtaining information indicating one or more of:
 i) the sequence of the rs3750920 SNP in the TOLLIP gene; 
 ii) the sequence of the rs5743894 SNP in the non-coding region of the TOLLIP gene; or 
 iii) the sequence of the rs35705950 SNP in the non-coding region of the MUC5B gene; 
   b) treating the patient with NAC or PAN when the sequence of SNP rs3750920 is determined to be homozygous or heterozygous thymine; or treating the patient with NAC when the sequence of SNP rs5743894 or SNP rs35705950 is determined to be homozygous or heterozygous guanine or thymine, respectively; or   c) not treating the patient with NAC or PAN and/or determining that NAC and/or PAN is contraindicated when the sequence of SNP rs3750920 is determined to be homozygous cytosine; or not treating the patient with NAC and/or determining that NAC is contraindicated when the sequence of SNP rs5743894 or SNP rs35705950 is determined to be homozygous alanine or guanine, respectively.   
     
     
         20 . The method of  claim 19 , wherein the patient is treated with NAC when the patient is determined to be homozygous or heterozygous for thymine at the single nucleotide polymorphism rs3750920 or wherein NAC therapy is determined to be contraindicated when the patient is determined to be homozygous for cytosine at the single nucleotide polymorphism rs3750920. 
     
     
         21 . The method of  claim 19 , wherein position 3074 upstream of genomic DNA of MUC5B gene has been sequenced, position 581 in the nucleotide coding sequence of TOLLIP has been sequenced, and/or position 6120 in genomic DNA of the TOLLIP gene has been sequenced. 
     
     
         22 . The method of  claim 19 , wherein sequences were obtained by amplifying a nucleic acid sequence complementary or identical to a region of the MUC5B genomic DNA 3074 nucleotides upstream of the MUC5B gene, a region of the TOLLIP coding sequence that comprises position 581, and/or a region of the genomic DNA of the TOLLIP gene that comprises position 6120. 
     
     
         23 . The method of  claim 22 , wherein amplifying comprises using polymerase chain reaction (PCR). 
     
     
         24 - 28 . (canceled) 
     
     
         29 . The method of  claim 19 , wherein the patient has symptoms of or has been diagnosed with idiopathic pulmonary fibrosis. 
     
     
         30 - 36 . (canceled)